The six-minute walk test predicts cardiorespiratory fitness in individuals with aneurysmal subarachnoid hemorrhage

Wouter J. Harmsen, Gerard M. Ribbers, Jorrit Slaman, Majanka H. Heijenbrok-Kal, Ladbon Khajeh, Fop van Kooten, Sebastiaan J. C. M. M. Neggers & Rita J. van den Berg-Emons


To link to this article: https://doi.org/10.1080/10749357.2016.1260263

© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Published online: 05 Dec 2016.

Submit your article to this journal

Article views: 888

View Crossmark data

Citing articles: 1 View citing articles

Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ytsr20
The six-minute walk test predicts cardiorespiratory fitness in individuals with aneurysmal subarachnoid hemorrhage

Wouter J. Harmsena,b, Gerard M. Ribbersa,b, Jorrit Slamanb, Majanka H. Heijenbrok-Kalb, Ladbon Khajehc, Fop van Kootenc, Sebastiaan J. C. M. M. Neggersd and Rita J. van den Berg-Emonsa,b

Rijnland Rehabilitation Institute, Rotterdam, The Netherlands; bDepartment of Rehabilitation Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; cDepartment of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; dDepartment of Endocrinology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

ABSTRACT

Background: Peak oxygen uptake (VO_{2peak}) established during progressive cardiopulmonary exercise testing (CPET) is the "gold-standard" for cardiorespiratory fitness. However, CPET measurements may be limited in patients with aneurysmal subarachnoid hemorrhage (a-SAH) by disease-related complaints, such as cardiovascular health-risks or anxiety. Furthermore, CPET with gas-exchange analyses require specialized knowledge and infrastructure with limited availability in most rehabilitation facilities.

Objectives: To determine whether an easy-to-administer six-minute walk test (6MWT) is a valid clinical alternative to progressive CPET in order to predict VO_{2peak} in individuals with a-SAH.

Methods: Twenty-seven patients performed the 6MWT and CPET with gas-exchange analyses on a cycle ergometer. Univariate and multivariate regression models were made to investigate the predictability of VO_{2peak} from the six-minute walk distance (6MWD).

Results: Univariate regression showed that the 6MWD was strongly related to VO_{2peak} (r = 0.75, p < 0.001), with an explained variance of 56% and a prediction error of 4.12 ml/kg/min, representing 18% of mean VO_{2peak}. Adding age and sex to an extended multivariate regression model improved this relationship (r = 0.82, p < 0.001), with an explained variance of 67% and a prediction error of 3.67 ml/kg/min corresponding to 16% of mean VO_{2peak}.

Conclusions: The 6MWT is an easy-to-administer submaximal exercise test that can be selected to estimate cardiorespiratory fitness at an aggregated level, in groups of patients with a-SAH, which may help to evaluate interventions in a clinical or research setting. However, the relatively large prediction error does not allow for an accurate prediction in individual patients.

OPEN ACCESS

KEYWORDS

Six-min walk test; 6MWT; CPET; cardiopulmonary exercise test; cardiorespiratory fitness; rehabilitation; VO_{2peak}; peak oxygen consumption; standard error of the estimate; subarachnoid hemorrhage

INTRODUCTION

An aneurysmal subarachnoid hemorrhage (a-SAH) is a subtype of stroke caused by a ruptured intracranial aneurysm. The incidence rates have remained stable over decades ranging from 6 to 8 per 100,000 person-years. It is reported that a-SAH has long-term consequences such as fatigue, depressive symptoms and problems in cognitive functioning that may persist four years post-onset. Furthermore, half of the patients experience problems in resuming previous activities, 64% report on one or more participation restrictions, and only one-third is able to fully resume their previous occupation.

Previously, we showed that the cardiorespiratory fitness was approximately 30% lower in patients with a-SAH compared to control subjects. The beneficial health effects of improved cardiorespiratory fitness in individuals with stroke, not caused by a-SAH, are well-recognized and exercise training has become
an integral component of stroke rehabilitation.9–11 However, the benefits of improved cardiorespiratory fitness remain to be established in individuals with a-SAH. The assessment of cardiorespiratory fitness may help to target and improve rehabilitation programs for individuals with a-SAH.

The gold standard for measuring cardiorespiratory fitness is peak oxygen uptake (VO₂peak) obtained with indirect calorimetry during progressive cardiopulmonary exercise testing (CPET).12 However, disease-related complaints, such as cardiovascular health risks or anxiety, may limit the use of progressive CPET in individuals with a-SAH.13,14 Moreover, progressive CPET measurements with gas-exchange analyses require specialized knowledge and infrastructure, with limited availability in most rehabilitation facilities.

The six-minute walk test (6MWT) is an easy-to-administer submaximal exercise test, in which the covered distance walked within six minutes is measured.15 The six-minute walk distance (6MWD) is found to be predictive of VO₂peak in patients with cardiopulmonary disorders.16–18 In patients with stroke, not caused by a-SAH, the 6MWD seems to be less predictive of VO₂peak. Associations between 6MWD and VO₂peak range from 0.34 to 0.74.19 The 6MWD seems to be determined more by impaired walking capacity, than by limited VO₂peak in these patients.20–22 Because patients with a-SAH usually do not suffer from impairments that directly affect walking capacity,23,24 the 6MWD may be more indicative of VO₂peak in these patients. If this is so, the 6MWT may be an easy-to-use instrument to assess cardiorespiratory fitness after a-SAH and will be of great value in daily clinical practice.

The present study investigates the relationship between the 6MWD and VO₂peak, and examines whether the 6MWD can predict VO₂peak in individuals with a-SAH. We hypothesize that the 6MWD is a predictive measure of VO₂peak in individuals with a-SAH.

Methods

Setting and participants
This cross-sectional study, entitled HIPS-Rehab, was part of the longitudinal observational study: “Hypotuitarism In Patients after Subarachnoid hemorrhage study (HIPS).”25 The present study describes measures of physical fitness that were obtained six months after a-SAH. The study was approved by the Medical Ethics Committee of the Erasmus University Medical Center, and all participants gave written informed consent.

Individuals with a-SAH admitted to the department of Neurology of the Erasmus Medical Center between June 2009 and June 2012 were eligible for inclusion when they were discharged from the Intensive Care Unit and aged ≥18 years. Diagnosis of a-SAH was confirmed by computerized tomography (CT) of the brain and, in cases with negative CT, by lumbar puncture. Presence and location of the aneurysm was determined by CT angiography and/or a digital subtraction angiography.

Excluded from the study were patients meeting any of the following criteria: (1) hypothalamic or pituitary disease diagnosed prior to a-SAH; (2) history of cranial irradiation; (3) trauma capitis prior to a-SAH; (4) other intracranial lesion apart from a-SAH; or (5) other medical or psychiatric condition or laboratory abnormality that may interfere with the outcome of the study. Additional exclusion criteria regarding the CPET measurements were: aged ≥70 years, and absolute contra-indication for CPET.

Procedure
Contra-indications and health risks for physical exercise testing were examined by the treating physician using the guidelines for exercise testing and prescription, established by the American College of Sports Medicine (ACSM)26 and the Physical Activity Readiness Questionnaire (PAR-Q).27 Hereafter, the 6MWT and progressive CPET were performed sequentially in this order. Sufficient resting periods were provided between the tests. A sports physician served as an emergency back-up during the progressive CPET.

Six-minute walk test
The 6MWT is an easy-to-administer submaximal exercise test and was applied as described by the American Thoracic Society.28 The 6MWT showed good to excellent test–retest reliability after stroke.29 Participants were instructed to walk as far as they could along a 30-m indoor, continuous track with a hard surface during a 6-min period. The 6MWT was not practiced beforehand, since this resembles clinical practice. Consistent encouragement was provided after each minute. Participants were allowed to take rest during the test, but were instructed to resume walking as soon as they were able to do so.28 The 6MWD (m) was registered at the end of the test. Heart rate (HR) was recorded using a HR monitor.

Cardiopulmonary exercise test
Progressive CPET was performed on an electronically braked cycle ergometer, which is considered feasible and safe in individuals with stroke who underwent pre-test medical screening.30 A ramp protocol was implemented which was preceded by a four-min warm-up. Hereafter, the resistance increased every 10 s (for females: 12 W/min, for males: 16 W/min) to ensure that volitional exhaustion was reached within 8–14 min. The participants were instructed to pedal at a rate of 60–70 revolutions/min. CPET was terminated when participants voluntary stopped or were unable to maintain the target pedal rate. CPET could also be terminated because of increased health risks, as prescribed in the guidelines of the ACSM.31

During progressive CPET, blood pressure was measured for safety reasons using an automatic system, and heart function was monitored continuously with a 12-lead electrocardiogram. Gas-exchange analyses were applied by indirect calorimetry using a breath-by-breath oximetry analysing system. Before each measurement, volume and gas calibrations were performed. VO₂peak was defined as the highest mean oxygen uptake during 30 s of exercise and was expressed in absolute VO₂peak (mL/min) and VO₂peak per kg body mass (mL/kg/min).

The following criteria were used to objectively determine the performance of maximal exercise testing: (1) respiratory exchange ratio (RER) > 1.0,32 or (2) peak heart rate (HRpeak) within 10 beats per minute (bpm) of the age-predicted maximum heart rate (HRmax), calculated from the formula of Tanaka et al.:
HRmax = 208 – [0.7 × age]. As β-blocker medication reduces HRmax by 25–30%, the equation was adjusted for those with β-blocker medication: HRmax = 0.7 [208 – (0.7 × age)].

Clinical characteristics

The following clinical characteristics were collected to describe the study population: World Federation of Neurologic Surgeons (WFNS) grade, Glasgow Coma Scale (GCS) score, location of aneurysm, treatment modality of the aneurysm, and presence of hypopituitarism (yes/no) or hydrocephalus (yes/no). Additionally, neurologic comorbidity (paresis or spasticity) was examined and body mass index (BMI) was calculated from height and body mass (kg/m²).

Statistical analyses

Participants that met the objective criteria for maximal exercise testing were included in the final analyses. All data are expressed as mean (SD) unless otherwise indicated. The assumptions for normality and linear regression analysis were met. In order to compare clinical characteristics of participants versus non-participants, independent t-tests were used for continuous data and chi-square tests for categorical data.

A univariate linear regression model was performed using VO2peak as dependent variable and 6MWD (m) as independent variable. In a multivariate linear regression model age and sex were added using step-wise regression with variables being added in a forward model. The explained variance (r²) and the correlation coefficient (r) were analyzed. Although there are no hard rules to describe correlational strength, we considered a correlation coefficient of r > 0.70 as a strong correlation, representing a good estimation of VO2peak from 6MWD at an aggregated group level. Furthermore, the standard error of the estimate (SEE), as a percentage of mean VO2peak, was calculated to analyze the magnitude of the prediction error which reflects the prediction accuracy at an individual level.

Additionally, paired samples t-test was used to compare the 6MWD with normative values which were calculated from the formula established by Enright et al. All analyses were performed using IBM SPSS Statistics, version 20, and a probability value of p < 0.05 was considered statistically significant.

Results

Between June 2009 and June 2012, 241 patients were admitted to the ICU with a diagnosis of aSAH, 84 were included in HIPS from which 52 volunteered to participate in HIPS-Rehab. Participants in HIPS-Rehab (n = 52) did not differ from non-participants (n = 32) with regard to: sex (p = 0.291), age (p = 0.996), WFNS-grade (p = 0.505) and GCS score at admission (p = 0.136), the location of the aneurysm (p = 0.469), the administered treatment modality (p = 0.489), and the presence of hypopituitarism (p = 0.353) or hydrocephalus (p = 0.559).

In total, 27 successful measurements of both 6MWT and CPET were analyzed (52%). Of the original sample nine patients were aged >70 years, seven could not perform CPET because of logistic reasons, five showed absolute contraindications to CPET, two did not meet the objective criteria for maximal physical exertion, one was not able to perform CPET because of an additional injury and another one could not perform 6MWT because of visual impairment. Although participants included in the analyses were younger (mean age difference 6.8 years, 95% CI – 12.94 to –0.057, p = 0.033), there were no significant differences compared to those who were excluded. Table 1 presents characteristics of the participants. The majority had a ruptured aneurysm in the anterior circulation (63%), most underwent endovascular coiling (78%), and 23 (85%) were graded to WFNS I or II with a mean GCS score of 13.7 (2.3). Participants did not show neuro–motor deficits such as paresis or spasticity.

Although 21 participants (78%) had an increased health risk for physical exercise, there were no serious unexpected side-effects observed during or after the 6MWT or the progressive CPET. Outcome measures of 6MWT and CPET are presented in Table 2. Mean 6MWD was 498 (98) m, which is significantly lower than the calculated mean norm values (=557 (70) m; 95% CI for the difference = –99.1 to –18.6, p = 0.006). HR at the end of 6MWT was 114 (20) bpm, reflecting 67% of predicted maximum HR (= 171 (6) bpm). Results for CPET measurement showed a mean VO2peak of 22.3 (6.0) mL/kg/min, with a mean HRpeak of 152 (24) bpm, reflecting 89% of predicted HRmax (= 171 (6) bpm). The univariate linear regression model, with VO2peak as dependent variable and 6MWD as independent variable revealed a strong relationship (r = 0.75, B = 0.05, 95% CI for B = 0.03–0.06, p < 0.001), with an explained variance of 56% (Table 3). SEE was 4.12 ml/kg/min, representing 18% of mean VO2peak. Figure 1 shows the relationship between VO2peak and 6MWD.

The extended multivariate linear regression model was significant (p < 0.001), with an explained variance of 67% and a SEE of 3.67 ml/kg/min, representing 16% of mean VO2peak (Table 4). In addition to 6MWD (B = 0.04, 95% CI for

Table 1. Clinical characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Individuals with aSAH (n = 27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male (%)</td>
<td>8 (30%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.0 (8.9)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74.8 (10.3)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.9 (3.7)</td>
</tr>
<tr>
<td>WFNS grade (%)</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>14 (52%)</td>
</tr>
<tr>
<td>II</td>
<td>9 (33%)</td>
</tr>
<tr>
<td>III</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>3 (11%)</td>
</tr>
<tr>
<td>V</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>GCS score</td>
<td>13.7 (2.3)</td>
</tr>
<tr>
<td>Location aneurysm (%)</td>
<td></td>
</tr>
<tr>
<td>Anterior circulation</td>
<td>17 (63%)</td>
</tr>
<tr>
<td>Posterior circulation</td>
<td>10 (37%)</td>
</tr>
<tr>
<td>Aneurysm treatment, n (%)</td>
<td></td>
</tr>
<tr>
<td>Clipping</td>
<td>6 (22%)</td>
</tr>
<tr>
<td>Endovascular treatment*</td>
<td>21 (78%)</td>
</tr>
<tr>
<td>Complications following aSAH</td>
<td></td>
</tr>
<tr>
<td>Hydrocephalus, n (%)</td>
<td>8 (30%)</td>
</tr>
<tr>
<td>Growth Hormone Deficiency, n (%)</td>
<td>2 (7%)</td>
</tr>
<tr>
<td>Re-bleed</td>
<td>0</td>
</tr>
<tr>
<td>Delayed cerebral ischemia</td>
<td>3 (11%)</td>
</tr>
</tbody>
</table>

Note: BMI, Body Mass Index (kg/m²); WFNS grade, World Federation of Neurologic Surgeons grading system for subarachnoid hemorrhage scale.

*Endovascular treatment is also known as coiling.
error representing 16% of mean VO$_{2\text{peak}}$. Since post-stroke exercise programs improve cardiorespiratory fitness by 9–23%, we consider the prediction error of 16% too large to accurately predict VO$_{2\text{peak}}$ at an individual level. However, the 6MWT can be used to predict cardiorespiratory fitness at an aggregated level in groups of patients with a-SAH in clinical and research settings.

According to Outermans et al., correlation coefficients between VO$_{2\text{peak}}$ and 6MWD in patients with stroke, not caused by a-SAH, range from 0.34 to 0.74. They showed that the relationship is more determined by balance problems and neuro-motor impairments, which affect the walking ability, than by a limited VO$_{2\text{peak}}$. Patterson et al. found that the variance in 6MWD in individuals with stroke was explained by VO$_{2\text{peak}}$ for those who walked more quickly, and by balance for those who walked more slowly. In the present study, the relatively strong relationship between 6MWD and VO$_{2\text{peak}}$ can be explained by the fact that individuals with a-SAH have relatively mild neurologic morbidity that did not affect the walking ability.

The present findings are in line with studies in patients with cardiopulmonary disorders. Studies reported correlation coefficients for the relationship between 6MWD and VO$_{2\text{peak}}$ that ranges from 0.68 to 0.82. Ross et al. studied the predictability of VO$_{2\text{peak}}$ from the 6MWD by analyzing the magnitude of the SEE across 10 different studies, including 1,083 cardiopulmonary patients. They recognized moderate-to-strong relationships and reported on poor prediction accuracies as well; they concluded that the 6MWT can be used to estimate mean VO$_{2\text{peak}}$ at an aggregated level, but that the 6MWT cannot predict VO$_{2\text{peak}}$ at an individual level.

In patients with a-SAH, the mean 6MWD was found to be 498 m, which is higher compared to individuals with other types of stroke (6MWD ranging from 216 to 401 m). However, the mean 6MWD is 25% lower compared to that of sex and age-matched norm values, suggesting compromised cardiorespiratory fitness.

Five participants had absolute contra-indications for progressive CPET and the majority had increased health risks for

### Table 2. Results of the six-min walk test and cardiopulmonary exercise test.

<table>
<thead>
<tr>
<th>Variable</th>
<th>6MWT (n = 27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6MWD (m)</td>
<td>498 (98)</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>114 (20)</td>
</tr>
<tr>
<td>Time until VO$_{2\text{peak}}$ (min:sec)</td>
<td>09:45 (01:50)</td>
</tr>
<tr>
<td>VO$_{2\text{peak}}$ (mL/min)</td>
<td>1664.4 (500.8)</td>
</tr>
<tr>
<td>VE$_{\text{peak}}$ (L/min)</td>
<td>22.3 (6.0)</td>
</tr>
<tr>
<td>Maximum Load (W)</td>
<td>70.4 (23.7)</td>
</tr>
<tr>
<td>HR$_{\text{peak}}$ (bpm)</td>
<td>132.9 (44.7)</td>
</tr>
<tr>
<td>RER</td>
<td>152 (24)</td>
</tr>
<tr>
<td>RER</td>
<td>1.15 (0.08)</td>
</tr>
</tbody>
</table>

Note: 6MWT, six-min walk test; 6MWD, six-min walk distance; HR, heart rate; bpm, beats per minute; VO$_{2\text{peak}}$, peak oxygen uptake; VE$_{\text{peak}}$, peak minute ventilation; HR$_{\text{peak}}$, peak heart rate; RER, respiratory exchange ratio.

### Table 3. Univariate linear regression analysis with VO$_{2\text{peak}}$ (ml/kg/min) as dependent variable and the six-min walk distance (6MWD) as independent variable.

<table>
<thead>
<tr>
<th>Variable</th>
<th>B (95% CI) $^\dagger$</th>
<th>p-value</th>
<th>$r^2$</th>
<th>SEE $^\times$ 100 $^\dagger$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>−0.70 (0.03 to 0.06)</td>
<td>&lt;0.001</td>
<td>0.75</td>
<td>4.12</td>
</tr>
<tr>
<td>6MWD (m)</td>
<td>0.05</td>
<td></td>
<td>0.56</td>
<td>18%</td>
</tr>
</tbody>
</table>

Notes: CI, Confidence Interval; SEE, standard error of the estimates.$^\dagger$Unstandardized B-coefficients. $^\dagger$SEE expressed as percentage of mean VO$_{2\text{peak}}$.

B = 0.03–0.06, $p < 0.001$, age significantly contributed to the prediction of VO$_{2\text{peak}}$ ($B = −0.21$, 95% CI for $B = −0.38$ to −0.04, $p = 0.017$), whereas sex did not ($B = 1.52$, 95% CI for $B = −1.76$ to 4.80, $p = 0.349$).

### Discussion

The present study examined whether the 6MWT is a valid alternative to progressive CPET to predict the cardiorespiratory fitness after a-SAH. A significant, strong correlation was found between the 6MWD and VO$_{2\text{peak}}$ ($r = 0.82$), with a prediction error representing 16% of mean VO$_{2\text{peak}}$. Since post-stroke exercise programs improve cardiorespiratory fitness by 9–23%, we consider the prediction error of 16% too large to accurately predict VO$_{2\text{peak}}$ at an individual level. However, the 6MWT can be used to predict cardiorespiratory fitness at an aggregated level in groups of patients with a-SAH in clinical and research settings.

According to Outermans et al., correlation coefficients between VO$_{2\text{peak}}$ and 6MWD in patients with stroke, not caused by a-SAH, range from 0.34 to 0.74. They showed that the relationship is more determined by balance problems and neuro-motor impairments, which affect the walking ability, than by a limited VO$_{2\text{peak}}$. Patterson et al. found that the variance in 6MWD in individuals with stroke was explained by VO$_{2\text{peak}}$ for those who walked more quickly, and by balance for those who walked more slowly. In the present study, the relatively strong relationship between 6MWD and VO$_{2\text{peak}}$ can be explained by the fact that individuals with a-SAH have relatively mild neurologic morbidity that did not affect the walking ability.

The present findings are in line with studies in patients with cardiopulmonary disorders. Studies reported correlation coefficients for the relationship between 6MWD and VO$_{2\text{peak}}$ that ranges from 0.68 to 0.82. Ross et al. studied the predictability of VO$_{2\text{peak}}$ from the 6MWD by analyzing the magnitude of the SEE across 10 different studies, including 1,083 cardiopulmonary patients. They recognized moderate-to-strong relationships and reported on poor prediction accuracies as well; they concluded that the 6MWT can be used to estimate mean VO$_{2\text{peak}}$ at an aggregated level, but that the 6MWT cannot predict VO$_{2\text{peak}}$ at an individual level.

In patients with a-SAH, the mean 6MWD was found to be 498 m, which is higher compared to individuals with other types of stroke (6MWD ranging from 216 to 401 m). However, the mean 6MWD is 25% lower compared to that of sex and age-matched norm values, suggesting compromised cardiorespiratory fitness.

Five participants had absolute contra-indications for progressive CPET and the majority had increased health risks for
to accurately predict VO2peak in individual patients. Since the research purposes. However, the prediction error was too large evaluation of therapy programs in the clinical setting and for

No potential conflict of interest was reported by the authors.

Disclosure statement

The 6MWD was strongly related to VO2peak in patients with a-SAH. Therefore, the 6MWT can be used to predict mean VO2peak at an aggregated group level. This is relevant for the evaluation of therapy programs in the clinical setting and for research purposes. However, the prediction error was too large to accurately predict VO2peak in individual patients. Since the importance of cardiorespiratory fitness is well-recognized in stroke rehabilitation, easy-to-administer submaximal exercise tests need to be identified, to target and improve post-acute rehabilitation programs for individuals with a-SAH.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Dutch Brain Foundation [grant number 15F07.06].

Notes on contributors

Wouter J. Harmsen is a PhD candidate in the Department of Rotterdam Neurorehabilitation Research; the author has a strong interest in exercise rehabilitation, physical behavior, and epidemiological studies in patients with acquired brain injury.

Gerard M. Ribbers is a professor in neurorehabilitation in the Department of Rotterdam Neurorehabilitation Research; the author has a strong interest in rehabilitation medicine, neural plasticity, motor recovery, neuroengineering, assistive technology, and patient-related outcome measures after acquired brain injury.

Jorrit Slaman is a senior researcher in the Department of Rotterdam Neurorehabilitation Research; the author has an interest in patient related outcome measures, exercise rehabilitation, healthy lifestyles, and physical behavior in patients with neurologic conditions.

Majanka H. Heijenbrok-Kal is a senior epidemiologist in the Department of Rotterdam Neurorehabilitation Research; the author has a strong interest in patient related outcome measures after acquired brain injury, and extensive expertise in epidemiology, biostatistics, and data sciences.

Ladbon Khajeh is a PhD candidate in the Department of Neurology; the author has a strong interest in neurological diseases and studies the health consequences of pituitary dysfunction after aneurysmal subarachnoid hemorrhage.

Fop van Kooten is a neurologist and a senior researcher in the Department of Neurology and a member of the neurovascular research and training group; the author has an interest in neurological diseases.

Sebastiaan J. C. M. M. Neggers is an internist and endocrinologist in the Department of Endocrinology; the author has an interest in the effects of neuroendocrine dysfunction on health-related outcome.

Rita J. van den Berg-Emons is the study director of the research group MoveFit; the author has a strong interest in exercise rehabilitation, healthy lifestyles, physical fitness, and physical behavior in patients with chronic conditions.

References


Physical activity readiness questionnaire (par q) – (revised 2002). 2012


